601 related articles for article (PubMed ID: 27585680)
1. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
2. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Hatano T; Egawa S
Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574
[TBL] [Abstract][Full Text] [Related]
3. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
5. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Siroky BJ; Yin H; Babcock JT; Lu L; Hellmann AR; Dixon BP; Quilliam LA; Bissler JJ
Am J Physiol Renal Physiol; 2012 Sep; 303(6):F831-44. PubMed ID: 22791333
[TBL] [Abstract][Full Text] [Related]
6. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
[TBL] [Abstract][Full Text] [Related]
7. Rates of interventional procedures in patients with tuberous sclerosis complex-related renal angiomyolipoma.
Bissler J; Cappell K; Charles H; Song X; Liu Z; Prestifilippo J; Hulbert J
Curr Med Res Opin; 2015 Aug; 31(8):1501-7. PubMed ID: 26073843
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.
Swallow E; King S; Song J; Peeples M; Signorovitch JE; Liu Z; Prestifilippo J; Frost M; Kohrman M; Korf B; Krueger D; Sparagana S
Urology; 2017 Jun; 104():110-114. PubMed ID: 28263820
[TBL] [Abstract][Full Text] [Related]
9. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.
Kingswood JC; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D' Amato L; d'Augères GB; de Vries PJ; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC
Nephrol Dial Transplant; 2019 Mar; 34(3):502-508. PubMed ID: 29697822
[TBL] [Abstract][Full Text] [Related]
10. Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.
Henske EP
Pediatr Nephrol; 2005 Jul; 20(7):854-7. PubMed ID: 15856327
[TBL] [Abstract][Full Text] [Related]
11. Update on the Diagnosis and Management of Renal Angiomyolipoma.
Flum AS; Hamoui N; Said MA; Yang XJ; Casalino DD; McGuire BB; Perry KT; Nadler RB
J Urol; 2016 Apr; 195(4 Pt 1):834-46. PubMed ID: 26612197
[TBL] [Abstract][Full Text] [Related]
12. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
Henske EP; Rasooly R; Siroky B; Bissler J
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
15. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms.
Seyam RM; Bissada NK; Kattan SA; Mokhtar AA; Aslam M; Fahmy WE; Mourad WA; Binmahfouz AA; Alzahrani HM; Hanash KA
Urology; 2008 Nov; 72(5):1077-82. PubMed ID: 18805573
[TBL] [Abstract][Full Text] [Related]
16. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
[TBL] [Abstract][Full Text] [Related]
17. Huge renal angiomyolipomas in tuberous sclerosis complex.
Chan SY; Chan WK
Nephrology (Carlton); 2005 Aug; 10(4):382-6. PubMed ID: 16109086
[TBL] [Abstract][Full Text] [Related]
18. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
19. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action.
Pirson Y
Nephrol Dial Transplant; 2013 Jul; 28(7):1680-5. PubMed ID: 23413089
[No Abstract] [Full Text] [Related]
[Next] [New Search]